Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE: 600267)
Health Care · Pharmaceuticals · CN
CN¥11.75
+2.80% today · +11.7% 1Y
Zhejiang Hisun Pharmaceutical Co., Ltd. (SHSE: 600267) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $2.03B and employs 8,751 people.
Over the last twelve months the share price has gained 11.7%, trading between 9.35 and 15.00.
Tweenvest scores Zhejiang Hisun Pharmaceutical Co., Ltd. across four factors: quality 76/100, value 60/100, growth 23/100, dividend 45/100. Its strongest factor is quality.
600267 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.03B
- Revenue (TTM)
- $1.44B
- P/E
- 15.78
- EPS
- 0.74
- Dividend yield
- 1.79%
- Beta (5Y)
- 0.29
- 52-week high
- CN¥15.00
- 52-week low
- CN¥9.35
- Avg volume (3M)
- —
- Shares outstanding
- 1.16B
- Employees
- 8,751
- Next earnings
- —
About Zhejiang Hisun Pharmaceutical Co., Ltd.
Zhejiang Hisun Pharmaceutical Co., Ltd. is a Chinese enterprise engaged in the development, manufacturing, and distribution of a broad spectrum of pharmaceutical products. Its portfolio includes both active pharmaceutical ingredients (APIs) and finished drug formulations. The company's extensive therapeutic focus spans oncology, cardiovascular health, infectious diseases, liver support, orthopedics, parasitic infections, and immunosuppression. Additionally, Hisun Pharmaceutical addresses conditions such as weight management, viral infections, tuberculosis, and offers veterinary pharmaceuticals, among other specialized medical applications. Beyond its product lines, the firm provides product consultation and contract manufacturing/research (CMO/CRO) services. Established in 1956, Zhejiang Hisun Pharmaceutical Co., Ltd. is headquartered in Taizhou, China.
- ISIN
- CNE0000013Z2
- Founded
- 1956
- Listed since
- Jul 25, 2000
- Exchange
- Shanghai Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Granules India LimitedBSE: 532482 | $2.11B | Rs820.80 | -5.80% |
| Fujian Cosunter Pharmaceutical Co., Ltd.SZSE: 300436 | $2.10B | CN¥83.68 | -1.18% |
| Guobang Pharma Ltd.SHSE: 605507 | $2.08B | CN¥18.09 | -0.06% |
| Caplin Point Laboratories LimitedBSE: 524742 | $2.08B | Rs2,632.35 | -7.17% |
| Perrigo Company plcNYSE: PRGO | $2.01B | $14.50 | -0.34% |
| Trulieve Cannabis Corp.NYSE: TRLV | $2.00B | $10.37 | -3.80% |
| Structure Therapeutics Inc.NasdaqGM: GPCR | $1.97B | $25.67 | -7.23% |
| Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.SHSE: 603707 | $1.97B | CN¥8.19 | +6.36% |
Figures last refreshed Oct 4, 2026.